Diffuse Large B-Cell Lymphoma

Obtain an excisional lymph-node biopsy when feasible, or a sufficiently large core biopsy from the most metabolically active and accessible lesion. The diagnosis of DLBCL should be made only when pathology identifies clearly delineated sheets of large B cells. WileyWileyA British Society of Haematology Guideline

Request integrated hematopathology review with B-cell immunophenotyping and assessment of CD10, BCL6, MUM1/IRF4, BCL2, MYC, CD5, cyclin D1, and CD23 when morphology or phenotype raises an alternative mature B-cell neoplasm. CD10, BCL6, MUM1/IRF4, BCL2, and MYC expression patterns help distinguish DLBCL from mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, and other aggressive B-cell lymphomas, but immunophenotype alone does not establish the genetic high-grade category. ScienceDirectScienceDirectB Cell Lymphoma Cell - an overview

Specifically determine whether the presentation is de novo DLBCL or histologic transformation from an indolent B-cell lymphoma. Richter transformation represents conversion, usually to DLBCL, in patients with chronic lymphocytic leukemia; DLBCL can also arise through transformation of follicular lymphoma. A documented antecedent indolent lymphoma changes prognostic framing and should prompt review of prior pathology and treatment exposure. NEJM+1NEJMVenetoclax–Rituximab in Relapsed or Refractory Chronic ...WileyAmerican Journal of Hematology | Blood Research Journal | Wiley Online Library

Complete baseline staging with FDG-PET/CT and document extranodal disease, bulky disease, performance status, serum LDH, and International Prognostic Index. In POLARIX, bulky disease was defined as one or more lesions at least 7.5 cm in greatest diameter, and treatment randomization was stratified by IPI 2 versus 3-5 and bulk. NEJMNEJMPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Treat MYC, BCL2, and BCL6 rearrangement assessment as a standard component of DLBCL workup. Double-hit and triple-hit lymphomas, defined by MYC rearrangement with BCL2, BCL6, or both rearrangements, have poor outcomes with standard chemotherapy and warrant early discussion at a center experienced in aggressive B-cell lymphoma. ScienceDirect+1ScienceDirectResearch Article Diffuse Large B-Cell Lymphoma/High ...PubMedCAR-T Cell Therapy in Large B Cell Lymphoma

Assess for central nervous system involvement at baseline when neurologic symptoms or signs are present, and recognize CNS involvement as a high-risk feature. CNS relapse has been reported in approximately 5% of DLBCL and is associated with poor outcomes; patients with CNS involvement or double-/triple-hit features may require an altered treatment approach rather than routine management. PubMed+1PubMedPractical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across CanadaWileyE‐POSTERS - 2021 - Hematological Oncology

R-CHOP remains a curative-intent chemoimmunotherapy backbone for DLBCL. In the POLARIX trial, the comparator regimen comprised rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² with a 2-mg maximum, and prednisone 100 mg orally once daily on days 1-5 for six 21-day cycles, followed by two further rituximab-containing cycles. NEJMNEJMPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

For previously untreated DLBCL with IPI 2-5, consider pola-R-CHP: polatuzumab vedotin 1.8 mg/kg intravenously on day 1 plus rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and prednisone 100 mg orally on days 1-5, every 21 days for six cycles, followed by two additional rituximab-containing cycles. Polatuzumab replaces vincristine in this regimen. NEJMNEJMPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

POLARIX showed greater persistence of remission with pola-R-CHP than R-CHOP among patients achieving complete response, with a hazard ratio for relapse or death of 0.70 (95% CI, 0.50-0.98); overall survival did not differ significantly. Present this as a disease-control benefit rather than a demonstrated survival advantage. NEJMNEJMPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Do not postpone first-line therapy while waiting for every molecular result when the patient has clinically aggressive disease, but ensure MYC, BCL2, and BCL6 rearrangement testing is in process before the treatment course is fixed. Patients with double-hit or triple-hit genetics have poor outcomes with standard chemotherapy and should be managed with early high-risk lymphoma input. ScienceDirect+1ScienceDirectResearch Article Diffuse Large B-Cell Lymphoma/High ...PubMedCAR-T Cell Therapy in Large B Cell Lymphoma

At progression, obtain biopsy of an accessible active lesion when clinically feasible, particularly after a long remission, when imaging is discordant, or when transformation or an alternative process is plausible. Then classify the event by timing: refractory disease or relapse within 12 months of first-line treatment supports referral for second-line CAR T-cell therapy assessment; axicabtagene ciloleucel and lisocabtagene maraleucel are used in this setting. PubMedPubMedCAR-T Cell Therapy in Large B Cell Lymphoma

Refer early to a CAR T-cell center rather than exhausting multiple ineffective systemic regimens. Bridging chemoimmunotherapy or radiation therapy may be used to reduce tumor burden before CAR T-cell infusion, but treatment selection must preserve fitness for lymphodepletion and cellular therapy. PubMedPubMedCAR-T Cell Therapy in Large B Cell Lymphoma

For relapsed or refractory DLBCL after at least two systemic lines, CD20×CD3 bispecific antibodies offer an important option for patients who previously received CAR T-cell therapy or are ineligible for or unable to receive it. Glofitamab is administered intravenously for a fixed duration of up to 12 21-day cycles, totaling 13 doses over 36 weeks, unless progression or unacceptable toxicity occurs. PubMedPubMedPractical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada

Epcoritamab is a subcutaneous, indefinite-duration treatment schedule: weekly for 3 months, then every 2 weeks for 6 months, with 24 doses over the initial 36 weeks; subsequent administration continues according to the treatment schedule until progression or unacceptable toxicity. Consider treatment logistics, expected adherence, cytopenias, infection risk, and local capability for cytokine-release syndrome management when choosing between a fixed-duration intravenous and ongoing subcutaneous strategy. PubMed+1PubMedPractical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across CanadaPubMedComprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies

After first-line immunochemotherapy, interpret residual or recurrent radiographic abnormalities in the context of clinical trajectory and obtain tissue confirmation when feasible before declaring relapse. This is particularly important when a new lesion emerges after a prolonged remission or when prior indolent lymphoma creates the possibility of recurrent low-grade disease rather than recurrent DLBCL.

Following CAR T-cell therapy, evaluate fever, hypotension, or hypoxia immediately for cytokine-release syndrome and assess new confusion, aphasia, or seizure for ICANS. Severe CRS and neurotoxicity occur in a clinically meaningful minority of recipients, so treatment should be delivered with rapid access to experienced toxicity management and inpatient escalation. PubMedPubMedBispecific Antibodies Versus Chimeric Antigen Receptor T ...

Monitor complete blood counts and infectious complications beyond the immediate treatment period after CAR T-cell or bispecific-antibody therapy. Prolonged neutropenia, anemia, thrombocytopenia, B-cell aplasia, and infection risk may persist, and hypogammaglobulinemia may justify immunoglobulin replacement in selected patients. PubMed+1PubMedBispecific Antibodies Versus Chimeric Antigen Receptor T ...PubMedComprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies